EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer

Hélène Lasolle, Christine Do Cao, Livia Lamartina, Abir Al Ghuzlan, Delphine Drui, Camille Buffet, Sophie Leboulleux, Segolène Hescot, Yann Godbert, Slimane Zerdoud, Renaud Ciappuccini, Arnaud Jannin und 2 weitere

Annales d'Endocrinologie · 2025

DOI: 10.1016/j.ando.2025.101733 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Annales d'Endocrinologie, 2025. Verfasst von Hélène Lasolle und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Université Lyon1, Lyon, France. Electronic address: helene.lasolle@chu-ly…. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Thyroid Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medullary thyroid carcinoma (MTC) accounts for 2-4% of thyroid cancers. It has the particularity of being a neuroendocrine tumor associated with a proto-oncogene germline RET mutation: germline in 20-25% of cases, somatic in 70-80% of metastatic sporadic cases. Locally advanced and metastatic MTCs are called "refractory". Individual prognosis is difficult, since the clinical behavior of the disease varies greatly from one patient to another. However, histological factors, such as high-grade forms, associated with greater risk of tumor progression and death, have been recently identified, and biological factors, such as the doubling time of plasma calcitonin, may help assess prognosis. Treatment of refractory medullary thyroid carcinoma has progressed considerably over recent years, with the advent of targeted therapies such as multi-kinase inhibitors and selective RET inhibitors. Management requires multidisciplinary expertise, and is tailored to the individual clinical situation patient, the molecular characteristics of the tumor, and the progression of the disease. These advances have led the ENDOCAN-TUTHYREF rare-cancer network of the French National Institute for Cancer (INCa), dedicated to refractory thyroid cancer, to draw up a set of consensus recommendations. This article focuses on refractory medullary thyroid cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, NeuroendocrineThyroid NeoplasmsHumansConsensusPrognosisProto-Oncogene MasProto-Oncogene Proteins c-retFrance

Stichwörter der Autor:innen

GeneticsMedullary thyroid carcinomaProto-oncogene RETRefractory thyroid cancerTargeted therapy

Substanzen

MAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins c-retRET protein, human

Autor:innen und Institutionen

  • Department of Endocrinology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Université Lyon1, Lyon, France. Electronic address: helene.lasolle@chu-lyon.fr.
  • Department of Endocrinology, Hôpital Claude-Huriez, CHRU de Lille, Lille, France. Electronic address: Christine.DOCAO@chu-lille.fr.
  • Département d'Imagerie Médicale, Service de Cancérologie Endocrinienne, Gustave-Roussy, 94805 Villejuif, France. Electronic address: Livia.LAMARTINA@gustaveroussy.fr.
  • Department of Medical Biology and Pathology, Gustave-Roussy, University Paris-Saclay, Villejuif, France. Electronic address: Abir.ALGHUZLAN@nice.unicancer.fr.
  • Department of Endocrinology, Hôpital Laennec, CHU de Nantes, Saint-Herblain, Nantes, France. Electronic address: Delphine.DRUI@chu-nantes.fr.
  • Thyroid and Endocrine Tumors Department, Thyroid Tumors Clinical Research Group, Pitié-Salpêtrière Hospital, Cancer Institute, Sorbonne University, Paris, France. Electronic address: camille.buffet@aphp.fr.

Zitieren

APA

Lasolle, H., Do Cao, C., Lamartina, L., Al Ghuzlan, A., Drui, D., Buffet, C., Leboulleux, S., Hescot, S., Godbert, Y., Zerdoud, S., Ciappuccini, R., Jannin, A., Hadoux, J., & Borson-Chazot, F. (2025). ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer. Annales d'Endocrinologie. https://doi.org/10.1016/j.ando.2025.101733

Vancouver

Lasolle H, Do Cao C, Lamartina L, Al Ghuzlan A, Drui D, Buffet C, et al. ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer. Annales d'Endocrinologie. 2025. doi:10.1016/j.ando.2025.101733

BibTeX
@article{Lasolle2025,
  author = {Lasolle, Hélène and Do Cao, Christine and Lamartina, Livia and Al Ghuzlan, Abir and Drui, Delphine and Buffet, Camille and Leboulleux, Sophie and Hescot, Segolène and Godbert, Yann and Zerdoud, Slimane and Ciappuccini, Renaud and Jannin, Arnaud and Hadoux, Julien and Borson-Chazot, Francoise},
  title = {ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer},
  journal = {Annales d'Endocrinologie},
  year = {2025},
  doi = {10.1016/j.ando.2025.101733}
}
Kostenlos starten →